SCHEMBL20605366

SCHEMBL20605366

COCC(=O)Nc1cccc(B(O)O)c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.65
SMN1; SMN2 Q16637 2/20 0.59
HPGD P15428 7/20 0.55
MAPT P10636 2/20 0.55
CYP2C19 P33261 1/20 0.55
ALOX12 P18054 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
ALDH1A1 P00352 4/20 0.51
MTNR1A P48039 1/20 0.50
MTNR1B P49286 1/20 0.50
KDM4C Q9H3R0 1/20 0.50
NPC1 O15118 1/20 0.49
KDM4E B2RXH2 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9495103 0.85 SMN1; SMN2 (0.71) SMN1; SMN2HPGDMAPTCYP2C19ALOX12
SCHEMBL6332545 0.85 KMT2A (0.68) NLRP3SMN1; SMN2HPGDMAPTCYP2C19
SCHEMBL6353539 0.83 RAB9A (0.63) NLRP3SMN1; SMN2MAPTCYP2C19MAPK1
SCHEMBL6333444 0.81 NPC1 (0.67) NLRP3SMN1; SMN2HPGDMAPTMAPK1
SCHEMBL3783971 0.81 NLRP3 (0.59) NLRP3SMN1; SMN2HPGDMAPK1ALDH1A1
SCHEMBL15985297 0.80 NLRP3 (0.59) NLRP3HPGDMAPTMAPK1ALDH1A1
SCHEMBL8622297 0.80 NLRP3 (0.58) NLRP3SMN1; SMN2MAPTMAPK1HTT
SCHEMBL14756770 0.80 NLRP3 (0.58) NLRP3MAPTMEN1KMT2A
SCHEMBL6579498 0.80 MAPK1 (0.68) SMN1; SMN2HPGDMAPTCYP2C19ALOX12
SCHEMBL7744399 0.80 NLRP3 (0.58) NLRP3MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107141293-B Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2022-09-23 CN disclosed
CN-115057861-A Nitrogen-containing heterocyclic compound, preparation method, intermediate, composition and application 上海医药集团股份有限公司 2022-09-16 CN disclosed
US-10828305-B2 Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2020-11-10 US disclosed
US-20190091226-A1 NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2019-03-28 US disclosed
EP-3424928-A1 NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190091226-A1 NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE ERBB2, EGFR, ERBB4 NLRP3 4401/4885SMN1; SMN2 3422/4885HPGD 1384/4885
US-10828305-B2 Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use ERBB2, EGFR, ERBB4 NLRP3 4401/4885SMN1; SMN2 3422/4885HPGD 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.